You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • OP0021 Efficacy and safety results of a phase iii study comparing fkb327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis

Citation Tools

Article menu

Download PDFPDF

Oral Presentations
Still breaking news on TNF inhibitors in rheumatoid arthritis
OP0021 Efficacy and safety results of a phase iii study comparing fkb327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Alten R, Glover J, Matsunaga N, et al
OP0021 Efficacy and safety results of a phase iii study comparing fkb327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis
Annals of the Rheumatic Diseases 2017;76:59.